Logo image
Drug-Induced Hypersensitivity Syndrome (DIHS)/ Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis
Journal article   Open access   Peer reviewed

Drug-Induced Hypersensitivity Syndrome (DIHS)/ Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis

N. Hama, R. Abe, A. Gibson and E.J. Phillips
The Journal of Allergy and Clinical Immunology: In Practice, Vol.10(5), pp.1155-1167
2022
pdf
DRESS.pdf7.49 MBDownloadView
Author’s Version Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DIHS/DRESS) is one example of a severe delayed T-cell mediated adverse drug reaction. DIHS/DRESS presents with fever, widespread rash and facial edema, organ involvement, and hematological abnormalities, including eosinophilia and atypical lymphocytosis. DIHS/DRESS is associated with relapse 2-4 weeks following acute symptoms, often coinciding with reactivation of prevalent chronic persistent human Herpesviruses (HHV) such as HHV-6, Epstein-Barr Virus, and cytomegalovirus (CMV). The mortality of DIHS/DRESS is up to 10% and often related to unrecognized myocarditis and CMV complications, with longer-term consequences that contribute to morbidity including autoimmune diseases such as thyroiditis. It is essential that all potential drug causes, including all new drugs introduced within the 8 weeks preceding onset of DIHS/DRESS symptoms, are identified. All potential drug culprits, as well as drugs that are closely related structurally to the culprit drug, should be avoided in the future. Systemic corticosteroids have remained the mainstay for the treatment of DIHS/DRESS with internal organ involvement. Steroid sparing agents, such as cyclosporine, mycophenolate mofetil, and monthly intravenous immune globulin, have been successfully used for treatment, and careful follow-up for CMV reactivation is recommended. Strong associations between HLA class I alleles and DIHS/DRESS predisposition include HLA-B*13:01 and dapsone, HLA-B*58:01 and allopurinol, and HLA-B*32:01 and vancomycin. These have opened a pathway for prevention, risk stratification, and earlier diagnosis. Single-cell sequencing and other studies of immunopathogenesis promise to identify targeted treatment approaches.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

20 File views/ downloads
166 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Highly Cited Paper 
Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.265 Dermatology - Skin Allergies
1.265.1140 Drug Hypersensitivity
Web Of Science research areas
Allergy
Immunology
ESI research areas
Clinical Medicine
Logo image